Related references
Note: Only part of the references are listed.Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model
Susan L. Baldwin et al.
PLOS ONE (2021)
A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guerin
Joshua S. Woodworth et al.
NATURE COMMUNICATIONS (2021)
PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study
Sodiomon B. Sirima et al.
LANCET INFECTIOUS DISEASES (2020)
The global prevalence of latent tuberculosis: a systematic review and meta-analysis
Adam Cohen et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial
Rhea N. Coler et al.
NPJ VACCINES (2018)
Malaria vaccine candidate based on Duffy-binding protein elicits strain transcending functional antibodies in a Phase I trial
Kavita Singh et al.
NPJ VACCINES (2018)
Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine
Miriam Tendler et al.
TROPICAL MEDICINE AND INFECTIOUS DISEASE (2018)
The occupational risk of tuberculosis in a low-prevalence population
S. Youakim
OCCUPATIONAL MEDICINE-OXFORD (2016)
Schistosomiasis vaccine candidate Sm14/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults
Marilia Santini-Oliveira et al.
VACCINE (2016)
From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE
Rhea N. Coler et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2015)
Prevalence of Latent Tuberculosis Infection among Medical Students in South Korea
Da Ho Jung et al.
TUBERCULOSIS AND RESPIRATORY DISEASES (2012)
Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant
Rhea N. Coler et al.
PLOS ONE (2011)
A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2-A GLURP-MSP3 fusion protein malaria vaccine candidate
Susana Lousada-Dietrich et al.
VACCINE (2011)
Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations
Ryan C. Anderson et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2010)
Occupational Infection in Korea
Yun Kyung Chung et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2010)
A Synthetic Adjuvant to Enhance and Expand Immune Responses to Influenza Vaccines
Rhea N. Coler et al.
PLOS ONE (2010)
A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug-Resistant Mycobacterium tuberculosis
Sylvie Bertholet et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Optimized subunit vaccine protects against experimental leishmaniasis
Sylvie Bertholet et al.
VACCINE (2009)
Enhanced humoral and Type 1 cellular immune responses with Fluzone® adjuvanted with a synthetic TLR4 agonist formulated in an emulsion
Susan L. Baldwin et al.
VACCINE (2009)
The success and failure of BCG - implications for a novel tuberculosis vaccine
P Andersen et al.
NATURE REVIEWS MICROBIOLOGY (2005)